| Bioactivity | TCJL37 is a potent, selective, and orally bioavailable TYK2 inhibitor with a Ki of 1.6 nM. TCJL37 can be used for the research of inflammatory bowel diseases (IBD)[1]. |
| Invitro | In cell-based assays, TCJL37 (Compound 37) shows IL-12 pSTAT4 EC50 of 224 nM. TCJL37 shows EC50s of 168 nM and 737 nM In human peripheral blood mononuclear cells (PBMC) and human whole blood assay, respectively[1]. |
| In Vivo | TCJL37 exhibits excellent oral exposure in CD-1 mice following oral administration (100 mg/kg). TCJL37 exhibits low clearance (1.0 mL/min/kg) in rat[1]. |
| Name | TCJL37 |
| CAS | 1258294-34-6 |
| Formula | C17H11ClF2N4O2 |
| Molar Mass | 376.74 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Jun Liang, et al. Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors. J Med Chem. 2013 Jun 13;56(11):4521-36. |
TCJL37
CAS: 1258294-34-6 F: C17H11ClF2N4O2 W: 376.74
TCJL37 is a potent, selective, and orally bioavailable TYK2 inhibitor with a Ki of 1.6 nM. TCJL37 can be used for the re
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.